163 related articles for article (PubMed ID: 34743383)
21. NFATc1 in mice represses osteoprotegerin during osteoclastogenesis and dissociates systemic osteopenia from inflammation in cherubism.
Aliprantis AO; Ueki Y; Sulyanto R; Park A; Sigrist KS; Sharma SM; Ostrowski MC; Olsen BR; Glimcher LH
J Clin Invest; 2008 Nov; 118(11):3775-89. PubMed ID: 18846253
[TBL] [Abstract][Full Text] [Related]
22. Investigating global gene expression changes in a murine model of cherubism.
Sharma T; Cotney J; Singh V; Sanjay A; Reichenberger EJ; Ueki Y; Maye P
Bone; 2020 Jun; 135():115315. PubMed ID: 32165349
[TBL] [Abstract][Full Text] [Related]
23. Mutations in SH3BP2, the cherubism gene, were not detected in central or peripheral giant cell tumours of the jaw.
Idowu BD; Thomas G; Frow R; Diss TC; Flanagan AM
Br J Oral Maxillofac Surg; 2008 Apr; 46(3):229-230. PubMed ID: 17544554
[TBL] [Abstract][Full Text] [Related]
24. Loss of Tankyrase-mediated destruction of 3BP2 is the underlying pathogenic mechanism of cherubism.
Levaot N; Voytyuk O; Dimitriou I; Sircoulomb F; Chandrakumar A; Deckert M; Krzyzanowski PM; Scotter A; Gu S; Janmohamed S; Cong F; Simoncic PD; Ueki Y; La Rose J; Rottapel R
Cell; 2011 Dec; 147(6):1324-39. PubMed ID: 22153076
[TBL] [Abstract][Full Text] [Related]
25. Cherubism: a systematic literature review of clinical and molecular aspects.
Chrcanovic BR; Guimarães LM; Gomes CC; Gomez RS
Int J Oral Maxillofac Surg; 2021 Jan; 50(1):43-53. PubMed ID: 32620450
[TBL] [Abstract][Full Text] [Related]
26. Novel treatment of a rare genetic bone disease.
McMahon MS
Orthopedics; 2007 Feb; 30(2):91. PubMed ID: 17323628
[No Abstract] [Full Text] [Related]
27. NFATc1 and TNFalpha expression in giant cell lesions of the jaws.
Amaral FR; Brito JA; Perdigão PF; Carvalho VM; de Souza PE; Gomez MV; De Marco L; Gomez RS
J Oral Pathol Med; 2010 Mar; 39(3):269-74. PubMed ID: 20002873
[TBL] [Abstract][Full Text] [Related]
28. Novel nucleotide mutation leading to a recurrent amino acid alteration in SH3BP2 in a patient with cherubism.
Sangu N; Shimosato T; Inoda H; Shimada S; Shimojima K; Ando T; Yamamoto T
Congenit Anom (Kyoto); 2013 Dec; 53(4):166-9. PubMed ID: 24712477
[TBL] [Abstract][Full Text] [Related]
29. Mutations of the SH3BP2 gene in 2 families of cherubism.
Tuna EB; Shimizu T; Seymen F; Yildirim M; Gencay K; Maeda T
Pediatr Dent; 2012; 34(3):198-202. PubMed ID: 22795151
[TBL] [Abstract][Full Text] [Related]
30. Loss-of-function
Kittaka M; Mizuno N; Morino H; Yoshimoto T; Zhu T; Liu S; Wang Z; Mayahara K; Iio K; Kondo K; Kondo T; Hayashi T; Coghlan S; Teno Y; Doan AAP; Levitan M; Choi RB; Matsuda S; Ouhara K; Wan J; Cassidy AM; Pelletier S; Nampoothiri S; Urtizberea AJ; Robling AG; Ono M; Kawakami H; Reichenberger EJ; Ueki Y
JBMR Plus; 2024 Jun; 8(6):ziae050. PubMed ID: 38699440
[TBL] [Abstract][Full Text] [Related]
31. A novel c.1255G>T (p.D419Y) mutation in SH3BP2 gene causes cherubism in a Turkish family.
Dinckan N; Guven Y; Kayserili H; Aktoren O; Uyguner OZ
Oral Surg Oral Med Oral Pathol Oral Radiol; 2012 Nov; 114(5):e42-6. PubMed ID: 23083484
[TBL] [Abstract][Full Text] [Related]
32. Microbe-Dependent Exacerbated Alveolar Bone Destruction in Heterozygous Cherubism Mice.
Kittaka M; Yoshimoto T; Schlosser C; Kajiya M; Kurihara H; Reichenberger EJ; Ueki Y
JBMR Plus; 2020 Jun; 4(6):e10352. PubMed ID: 32537546
[TBL] [Abstract][Full Text] [Related]
33. SH3BP2-related fibro-osseous disorders of the maxilla and mandible: A systematic review.
Kueper J; Tsimbal C; Olsen BR; Kaban L; Liao EC
Int J Oral Maxillofac Surg; 2022 Jan; 51(1):54-61. PubMed ID: 33941395
[TBL] [Abstract][Full Text] [Related]
34. Clinical and genetic analysis of patients with cherubism.
Machado RA; Pontes H; Pires FR; Silveira HM; Bufalino A; Carlos R; Tuji FM; Alves D; Santos-Silva AR; Lopes MA; Capistrano HM; Coletta RD; Fonseca FP
Oral Dis; 2017 Nov; 23(8):1109-1115. PubMed ID: 28644570
[TBL] [Abstract][Full Text] [Related]
35. Cherubism: best clinical practice.
Papadaki ME; Lietman SA; Levine MA; Olsen BR; Kaban LB; Reichenberger EJ
Orphanet J Rare Dis; 2012 May; 7 Suppl 1(Suppl 1):S6. PubMed ID: 22640403
[TBL] [Abstract][Full Text] [Related]
36. SH3BP2 is rarely mutated in exon 9 in giant cell lesions outside cherubism.
Lietman SA; Prescott NL; Hicks DG; Westra WH; Levine MA
Clin Orthop Relat Res; 2007 Jun; 459():22-7. PubMed ID: 17545756
[TBL] [Abstract][Full Text] [Related]
37. [Mutation detection in SH3BP2 gene in a cherubism family].
Li CY; Yu SF
Zhonghua Kou Qiang Yi Xue Za Zhi; 2006 Jun; 41(6):368-71. PubMed ID: 16836910
[TBL] [Abstract][Full Text] [Related]
38. Enhancement of B-cell receptor signaling by a point mutation of adaptor protein 3BP2 identified in human inherited disease cherubism.
Ogi K; Nakashima K; Chihara K; Takeuchi K; Horiguchi T; Fujieda S; Sada K
Genes Cells; 2011 Sep; 16(9):951-60. PubMed ID: 21794028
[TBL] [Abstract][Full Text] [Related]
39. A novel mutation of the SH3BP2 gene in an aggressive case of cherubism.
Carvalho VM; Perdigão PF; Pimenta FJ; de Souza PE; Gomez RS; De Marco L
Oral Oncol; 2008 Feb; 44(2):153-5. PubMed ID: 17368082
[TBL] [Abstract][Full Text] [Related]
40. Imatinib reduces non-alcoholic fatty liver disease in obese mice by targeting inflammatory and lipogenic pathways in macrophages and liver.
AlAsfoor S; Rohm TV; Bosch AJT; Dervos T; Calabrese D; Matter MS; Weber A; Cavelti-Weder C
Sci Rep; 2018 Oct; 8(1):15331. PubMed ID: 30333571
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
